Personalized medicine
In the field of 4P medicine (Predictive, Personalized, Preventive and Participatory), it is clear that personalized medicine is still at its infancy and its huge potential has yet to be unlocked. Alcimed is supporting key Healthcare players in addressing the promising field of personalized and precision medicine and promoting their development, from R&D to market access and adoption.
The challenges related to personalized medicine or precision medicine
-
What is personalized medicine and what is precision medicine?
Personalized medicine is defined as medical treatments tailored to the individual characteristics of each patient. It uses the individual’s genetic and phenotypic profile to guide decisions made on disease prevention, diagnosis, and treatment. Very recently, behavorial and social science has been used to add a new dimension to individual profiling.
Often used interchangeably with “personalized medicine”, the term “precision medicine” removes the incorrect notion that treatments are developed uniquely for each patient; the objective of personalized/precision medicine being rather to identify targeted therapies for specific patient groups.
-
What are the challenges related to personalized medicine?
Currently, personalized medicine is mostly targeting oncology indications (for example with CAR-T cells therapy) and genetic disorders (like cystic fibrosis or epilepsy). However, its use should expand to a broader range of applications. The global market of personalized medicine should thus reach $85.5 billion by 2025, growing at an annual rate of 9.9% (according to Grand View Research).
Several stakes around the expansion of personalized medicine can be thought of, among which:
Health Care Providers need to understand the patient’s genetic profile and get familiar with new technologies in order to personalize their approach to disease prevention, diagnosis, treatment, and management. However, lack of expertise in genomic testing is a key obstacle to precision medicine, many physicians struggling to accurately interpret test results without specialist assistance. Thus, a 2018 survey of 160 oncologists by Cardinal Health found that 60% of physicians who do not use genomic tests avoid them because of the difficulty of interpreting the genomic data.
How to educate and train HCPs to ensure an effective use of these new technologies? How to re-think the whole care organization in oncology and genetic disease in order to include precision medicine protocols? How will evolve the HCPs role and responsibilities – especially oncologists’- in the next future and how to support them? How to ensure hospitals hire the right specialists to support physicians in deciphering the data?
How to educate and train HCPs to ensure an effective use of these new technologies? How to re-think the whole care organization in oncology and genetic disease in order to include precision medicine protocols? How will evolve the HCPs role and responsibilities – especially oncologists’- in the next future and how to support them? How to ensure hospitals hire the right specialists to support physicians in deciphering the data?
The expansion of Big data (e.g. Multi-omics, images, device data, electronic health records...) is an obvious key driver of personalized medicine, and the creation of powerful systems to analyze it requires massive scientific and technical developments, in which multiple stakeholders have a role to play. Pharma and diagnostic companies need to rethink their R&D strategies to better understand diseases at a molecular level, develop tests to analyze genetic data and invest in tools to interpret it. They can also develop innovative partnerships; one key example being Roche’s partnership with Illumina in January 2021 to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology.
Governments also have a role to play by driving efforts in building genetic data sets and biobanks. Former US President Barack Obama launched for example the Precision Medicine Initiative in 2015; (which then became the “All of Us research program”), aiming at gathering health data from more than a million US volunteer-citizens.
Who will be the key stakeholders to partner with in the next future? How will the market for future tests evolve and how to be ready on time? Will the value lie in the test itself or in the insights generated?
Who will be the key stakeholders to partner with in the next future? How will the market for future tests evolve and how to be ready on time? Will the value lie in the test itself or in the insights generated?
Personalized medicine is based on individuals’ data, collected with diagnostics and behavioral devices. Therefore, some security concerns naturally arise regarding the way this data is used. Thus, the use of personalized medicine must be accompanied by appropriate basic policies, frameworks and tools. On the other hand, patient data privacy is dealt differently depending on the country, and stringent local data protection regulation could jeopardize the personalized medicine momentum.
How to ensure personal data protection when sharing them is needed to ensure patient care and research progress? How to deal with different national or regional data privacy regulation? How to educate patients on the need to share their genetic information for medical research?
How to ensure personal data protection when sharing them is needed to ensure patient care and research progress? How to deal with different national or regional data privacy regulation? How to educate patients on the need to share their genetic information for medical research?
The tremendous clinical benefit of personalized therapy has a cost: molecular diagnostics can be hundreds to thousands of dollars and are not always reimbursed, therapies themselves can cost up to hundreds of thousands of dollars a year. In the 2018 Cardinal Health study, many participating physicians said payers’ failure to cover the costs of genomic tests was as a common barrier to adoption of genomic testing.
The pharma industry needs therefore to partner with payers to develop new and affordable business models around personalized therapies. These should include appropriate reimbursement of molecular diagnostics, of the targeted therapies themselves, and of other personalized treatment protocols, to incentivize the practice of personalized medicine.
Which commercial model should be developed around precision medicine therapies? How to ensure access equity for all patients? How to define the best commercial model when smaller and smaller patient populations are considered? Who will own the future value of these therapies? Will traditional blockbusters markets become less profitable than smaller and exclusive markets of personalized medicines?
Which commercial model should be developed around precision medicine therapies? How to ensure access equity for all patients? How to define the best commercial model when smaller and smaller patient populations are considered? Who will own the future value of these therapies? Will traditional blockbusters markets become less profitable than smaller and exclusive markets of personalized medicines?
Precision medicine is changing the way clinical trials are and will be set up. As genetic testing helps create subtypes of diseases (like HER2-positive or triple-negative breast cancer), it is possible to test one drug on a big group of patients with different known types of the disease. In parallel, trials can also test targeted therapies specifically designed for patients with one given genetic variation. Thus, the use of one-person trials, known as “n of 1 trials,” is supporting personalized medicine research. The response rate is therefore likely to be higher as the studied treatment will target just one aspect of disease, for example one specific genetic mutation, that all the patients involved in the trial will have. By studying only people who can respond, researchers maximize the chance of good results.
How to re-design clinical trial to adapt to precision therapies? Will smaller trials with better results mean faster drug approvals?
How to re-design clinical trial to adapt to precision therapies? Will smaller trials with better results mean faster drug approvals?
How do we support you in your personalized or precision medicine projects?
At Alcimed, we support Pharma and Diagnostic players who wish to engage in personalized medicine or are already involved in this field.
Our clients’ diversity (pharma companies, biotechs, research centers, professional associations, national or European institutions,…), the geographical fields we explore, and the types of projects we develop, give us global in-depth understanding of the challenges faced in the field of healthcare and active insight into the development of personalized medicine.
We can support medical but also marketing and commercial teams in the definition of their R&D strategy, investigate the needs and stakes of HCPs and support their training, understand patients’ concerns and educate them, identify data sets available, investigate local regulation around patient data, identify key companies involved in data analytics to partner with, define business models for these therapies, support the collaboration with payers,… and many more!
The types of projects we carry out for our clients in this field are:
|
|
|
A project? Contact our explorers!
EXAMPLES OF RECENT PROJECTS CARRIED OUT FOR OUR CLIENTS IN THE FIELD OF PERSONALIZED MEDICINE
One of our clients, a specialty care player, wanted to pioneer in personalized medicine in its leading therapeutic area. Many questions aroused: is the field ready? Are we legitimate? How to tell the story around this positioning? To answer, we identified the scientific and medical elements supporting a need for personalized medicine, and then decipher whether our client’s history, portfolio, products and strengths would fit this medical need. Finally, we defined a strategic action plan enabling to activate its positioning in personalized medicine and structured a storytelling for the field force to use within the medical ecosystem.
For a consortium of public and private health actors, developing both diagnostic tests and personalized medicine therapies, Alcimed has deciphered the regulatory frameworks of the 3 areas considered (USA, Japan and EU5), to identify their specificities. A field investigation allowed us to specify the regulatory changes to be anticipated. The P&R (Price & Reimbursement) processes and their challenges were also examined in order to identify a preferential access model to optimize the launch of such individualized medicine products in each zone.
We assisted a leading player in the field of CAR-T therapies in preparing the launch of its new treatment and in defining its market access strategy in the United States, Canada and Europe. CAR-Ts are highly personalized technologies that require a high level of specialization to be delivered to patients, and therefore not all healthcare centers are ready to administer them. In this context, and in order to define the market access strategy for its new treatment, we helped our client to:
1. Understand and identify which centers would have the capacity to deliver CAR-Ts.
2. Analyze the bottlenecks for approval in the in-scope markets.
3. Consequently, define the actions to be implemented to ensure access to its new CAR-T therapy.
After an investigation conducted in more than 200 healthcare centers in the United States, Canada and Europe, our analysis brought us to recommend to our client the next key steps to be taken in order to develop the skills of each center and to promote rapid access to their new treatment.
1. Understand and identify which centers would have the capacity to deliver CAR-Ts.
2. Analyze the bottlenecks for approval in the in-scope markets.
3. Consequently, define the actions to be implemented to ensure access to its new CAR-T therapy.
After an investigation conducted in more than 200 healthcare centers in the United States, Canada and Europe, our analysis brought us to recommend to our client the next key steps to be taken in order to develop the skills of each center and to promote rapid access to their new treatment.
In order to develop personalized treatment in its very specific therapeutic area, one of our pharmaceutical client in Asia wanted to take benefits from potential existing genetic profiling campaigns. Alcimed identified and characterized all the current research programs and initiatives related to patient profiling on the targeted disease in the area. Given their expected and first actual results, we were able to assess the way these outcomes could influence personalized prescription practices, and the ability of our client to leverage on these results or programs. The results for our client? A comprehensive landscape of the ecosystem around patient profiling in its pathology, strong insights on prescribers and patients behaviors, and some partnering opportunities!
Founded in 1993, Alcimed is an innovation and new business consulting firm, specializing in innovation driven sectors: life sciences (healthcare, biotech, agrifood), energy, environment, mobility, chemicals, materials, cosmetics, aeronautics, space and defence.
Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.
Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.
Our dream? To build a team of 1,000 explorers, to design tomorrow's world hand in hand with our clients.
Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.
Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.
Our dream? To build a team of 1,000 explorers, to design tomorrow's world hand in hand with our clients.
Our explorations
- Proof of concept
- Voice of Customer (VOC)
- Activation
- Benchmark
- Business case
- Business development
- Business models
- Business plan
- Cluster study
- Collaborative projects
- Commercial strategy
- Competitive analysis
- Customer experience
- Diversification
- Dossier creation
- Due diligence
- Go to market
- Innovation consulting
- Innovation process
- Innovation strategy
- Learning expedition
- Market access
- Market study
- New offers
- New services
- Open innovation
- Opportunity evaluation
- Patient pathway
- Product innovation
- Product launch
- Regulatory framework analysis
- Roadmap
- Scouting
- Search for funding opportunities
- Search for partners
- State of the art
- Strategic audit
- Strategic foresight
- Strategic positioning
- Test and Learn
- Valorization
- Value proposition
- Workshops